CASE SERIES OF PATIENTS UNDER BIWEEKLY TREATMENT WITH LARONIDASE: A REPORT OF A SINGLE CENTER EXPERIENCE.
Sandra Obikawa KyosenLeny TomaHelena Bonciani NaderMarion Coting BragaVanessa Gonçalves PereiraSueli CanossaJoão Bosco PesqueroVânia D'AlmeidaAna Maria MartinsPublished in: Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo (2019)
Patients remained clinically stable under the alternative regimen, did not present elevation of urinary GAG nor any adverse event.Conclusions: The switch of dose regimen to 1.2 mg/kg EOW of laronidase was safe, and did not cause any clinical worsening in patients who had been previously under standard dose ERT.